このエントリーをはてなブックマークに追加
ID 67256
FullText URL
fulltext.pdf 1.07 MB
Author
Iwasaki, Keiichiro Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Nakamura, Kazufumi Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Kaken ID publons researchmap
Akagi, Satoshi Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID
Takaya, Yoichi Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID
Toda, Hironobu Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Miyoshi, Toru Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University ORCID Kaken ID publons
Yuasa, Shinsuke Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Abstract
Diabetes mellitus (DM) is a major risk and prognostic factor for heart failure (HF). Insulin resistance (IR) is an important component of DM, but the relationship between IR and HF prognosis has not yet been established across a wide variety of HF populations. We retrospectively evaluated the relationship between IR and clinical outcomes of HF patients at our hospital between 2017 and 2021. IR was defined as a homeostatic model assessment of IR (HOMA-IR) index >= 2.5, calculated from fasting blood glucose and insulin concentrations. The primary outcome was a composite of all-cause death and hospitalisation for HF (HHF). Among 682 patients included in the analyses, 337 (49.4%) had IR. The median age was 70 [interquartile range (IQR): 59-77] years old, and 66% of the patients were men. Among the patients, 41% had a left ventricular ejection fraction below 40%, and 32% had DM. The median follow-up period was 16.5 [IQR: 4.4-37.3] months. IR was independently associated with the primary outcome (HR: 1.91, 95% CI: 1.39-2.62, p < 0.0001), death (hazard ratio [HR]: 1.86, 95% confidence interval [CI]: 1.28-2.83, p < 0.01), and HHF (HR: 1.91, 95% CI: 1.28-2.83, p < 0.01). HOMA-IR is an independent prognostic factor of HF in a wide variety of HF populations.
Keywords
heart failure
insulin resistance
HOMA-IR
diabetes mellitus
Published Date
2024-06-14
Publication Title
Nutrients
Volume
volume16
Issue
issue12
Publisher
MDPI
Start Page
1888
ISSN
2072-6643
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© 2024 by the authors.
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.3390/nu16121888
License
https://creativecommons.org/licenses/by/4.0/
Citation
Iwasaki, K.; Nakamura, K.; Akagi, S.; Takaya, Y.; Toda, H.; Miyoshi, T.; Yuasa, S. Prognostic Implications of Insulin Resistance in Heart Failure in Japan. Nutrients 2024, 16, 1888. https://doi.org/10.3390/nu16121888